Washington – The molecule of a synthetic cannabinoid with immunomodulatory effects on cells of patients with multiple sclerosis opens the door to the possibility of developing a new generation of drugs for the treatment of this disease: is the scientific study just published by the professors Pasquale Annunziata and Federico Corelli from University of Siena in the international “Journal of Neuroimmunology”, published by Elsevier. The publication presents the results of the pharmacological effects of a new cannabinoid agonist, the COR167, on isolated immune cells from patients with multiple sclerosis. (9colonne)
